Last reviewed · How we verify
Dynacirc (ISRADIPINE)
Dynacirc (Isradipine) is a dihydropyridine calcium channel blocker, a small molecule that targets the voltage-dependent L-type calcium channel subunit alpha-1D. It was originally developed by Smithkline Beecham and is used to treat hypertensive disorders. Dynacirc is off-patent, with multiple generic manufacturers available. It has a half-life of 3.3 hours and bioavailability of 20%. Key safety considerations include its potential effects on heart rate and blood pressure.
At a glance
| Generic name | ISRADIPINE |
|---|---|
| Sponsor | Smithkline Beecham |
| Drug class | Dihydropyridine Calcium Channel Blocker [EPC] |
| Target | Voltage-dependent L-type calcium channel subunit alpha-1D |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Hypertensive disorder
Common side effects
- Headache
- Dizziness
- Edema
- Palpitations
- Fatigue
- Flushing
- Nausea
- Chest Pain
- Dyspnea
- Abdominal Discomfort
- Tachycardia
- Rash
Drug interactions
- itraconazole
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation (EARLY_PHASE1)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
- Parkinson's Disease Isradipine Safety Study (PHASE2)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients (PHASE2,PHASE3)
- Efficacy of Isradipine in Early Parkinson Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dynacirc CI brief — competitive landscape report
- Dynacirc updates RSS · CI watch RSS
- Smithkline Beecham portfolio CI